Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats

Cancer Chemother Pharmacol. 1998;42(4):280-6. doi: 10.1007/s002800050818.

Abstract

Purpose: SN-38, a metabolite of irinotecan hydrochloride (CPT-11), is considered to play a key role in the development of diarrhea as well as in the antitumor activity of CPT-11. We have previously found that the inhibition of beta-glucuronidase, which hydrolyzes detoxified SN-38 (SN-38 glucuronide) to reform SN-38, in the lumen by eliminating the intestinal microflora with antibiotics, markedly ameliorates the intestinal toxicity of CPT-11 in rats. In this study we compared the disposition of CPT-11 and its metabolites in rats treated with and without antibiotics.

Methods: Rats were given drinking water containing 1 mg/ml penicillin and 2 mg/ml streptomycin from 5 days before the administration of CPT-11 (60 mg/kg i.v.) and throughout the experiment. CPT-11, SN-38 glucuronide and SN-38 concentrations in the blood, intestinal tissues and intestinal luminal contents were determined by HPLC.

Results: Antibiotics had little or no effect on the pharmacokinetics of CPT-11, SN-38 glucuronide or SN-38 in the blood, or in the tissues or contents of the small intestine, which has less beta-glucuronidase activity in its luminal contents. In contrast, antibiotics markedly reduced the AUC1-24 h of SN-38 (by about 85%) in the large intestine tissue without changing that of CPT-11, and this was accompanied by a complete inhibition of the deconjugation of SN-38 glucuronide in the luminal contents.

Conclusions: These results suggest that SN-38, which results from the hydrolysis of SN-38 glucuronide by beta-glucuronidase in the intestinal microflora, contributes considerably to the distribution of SN-38 in the large intestine tissue, and that inhibition of the beta-glucuronidase activity by antibiotics results in decreased accumulation of SN-38 in the large intestine.

MeSH terms

  • Administration, Oral
  • Animals
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / pharmacology
  • Antineoplastic Agents, Phytogenic / administration & dosage
  • Antineoplastic Agents, Phytogenic / pharmacokinetics*
  • Antineoplastic Agents, Phytogenic / toxicity
  • Area Under Curve
  • Bacteria / enzymology
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives*
  • Camptothecin / blood
  • Camptothecin / pharmacokinetics
  • Camptothecin / toxicity
  • Diarrhea / microbiology
  • Diarrhea / prevention & control
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / pharmacokinetics*
  • Enzyme Inhibitors / toxicity
  • Glucuronidase / antagonists & inhibitors*
  • Injections, Intravenous
  • Intestine, Large / drug effects*
  • Intestine, Large / microbiology
  • Intestine, Small / drug effects*
  • Intestine, Small / microbiology
  • Irinotecan
  • Male
  • Penicillins / pharmacology
  • Rats
  • Rats, Wistar
  • Streptomycin / pharmacology

Substances

  • Anti-Bacterial Agents
  • Antineoplastic Agents, Phytogenic
  • Enzyme Inhibitors
  • Penicillins
  • Irinotecan
  • Glucuronidase
  • Camptothecin
  • Streptomycin